chAIron
Ana de Lillo, PhD, currently serves as an Advisor at chAIron, a Swiss HealthTech company since May 2025, focusing on leveraging artificial intelligence and real-world data to enhance drug development. Prior to this role, Ana was Vice President of International Strategic Business Growth at CENTOGENE, contributing to advancements in rare disease research from August 2023 to May 2025. Ana's extensive career includes significant positions at IQVIA and Quintiles, where leadership in real-world business partnerships and account management was emphasized. Earlier experiences include roles at OptumInsight and Chiltern International, involving business development, regulatory affairs, and clinical trial applications. Ana began a career in research as a Senior Postdoctoral Research Fellow at Guy's Hospital, gaining expertise in microbiology with a PhD from Universidad de Oviedo and additional management education from prestigious institutions.
This person is not in any teams
This person is not in any offices
chAIron
Leveraging information in real-world data, literature, and omics with artificial intelligence and engaging human expertise to expand the knowledge frontier of molecules by innovating in indication discovery to accelerate programs' potential, de-risk drug development, and raise asset value. Our expertise closes the translational gap between advanced analytics, complex biology, and market dynamics, providing our pharmaceutical and biotechnological partners with a holistic strategic roadmap of their assets and bringing treatments to patients sooner.